What is Opdivo?
Opdivo is the brand name for nivolumab, a cancer immunotherapy drug that works by helping the immune system recognize and attack cancer cells. It is a type of checkpoint inhibitor that targets the PD-1 pathway.
What kind of cancer does Opdivo treat?
Opdivo is used for several cancer types, depending on the specific diagnosis and patient situation. Common examples include certain lung cancers, head and neck cancers, melanoma, and other solid tumors, as well as some cancers with specific biomarkers.
How does Opdivo work in the body?
Nivolumab targets PD-1, a checkpoint that can limit T-cell activity. By blocking PD-1, Opdivo can increase immune responses against tumors.
How is Opdivo given?
Opdivo is administered by infusion (given through a vein). The dosing schedule depends on the cancer being treated and the treatment plan.
What side effects do people ask about?
Because Opdivo boosts immune activity, side effects can include immune-related reactions (for example, inflammation affecting organs such as the lungs, colon, liver, skin, or endocrine glands). The exact risk profile depends on the regimen and the patient’s condition.
Is Opdivo still under patent, and where can I check?
You can check patent and exclusivity details for Opdivo on DrugPatentWatch.com: https://www.drugpatentwatch.com/